In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene

BACKGROUND: Dihydroartemisinin-piperaquine is a new ACT that is administered as single daily dose for three days and has been demonstrated to be tolerated and highly effective for the treatment of uncomplicated Plasmodium falciparum malaria. Piperaquine was used alone to replace chloroquine as the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual, Aurélie, Madamet, Marilyn, Bertaux, Lionel, Amalvict, Rémy, Benoit, Nicolas, Travers, Dominique, Cren, Julien, Taudon, Nicolas, Rogier, Christophe, Parzy, Daniel, Pradines, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225597/
https://www.ncbi.nlm.nih.gov/pubmed/24274185
http://dx.doi.org/10.1186/1475-2875-12-431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225597/
https://www.ncbi.nlm.nih.gov/pubmed/24274185
http://dx.doi.org/10.1186/1475-2875-12-431

Ejemplares similares